International Journal of Cardiology国际心脏病学杂志
International Journal of Cardiology(英文缩写 INT J CARDIOL),ISSN 0167-5273,eISSN 1874-1754,中文译名:国际心脏病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 4.039 | Q2 |
| 2022 | 3.500 | Q2 |
| 2023 | 3.200 | Q2 |
| 2024 | 3.200 | Q2 |
| 2025 | 3.300 | Q2 |
International Journal of Cardiology 最新收录文献
-
2. Endothelial dysfunction and long-term outcomes in patients with myocardial infarction and non-obstructive coronary arteries.
PMID:日期:2026-11-15There is little information regarding the characteristics of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) in terms of coronary endothelial function and prognosis, as compared to patients with angina and non-obstructive coronaries (ANOCA). We assessed differences in clinical profile, endothelial function and prognosis between patients undergoing acetylcholine (ACH) testing for MINOCA or ANOCA. We combined two cohorts of patients undergoing ACH testing - ENDOCOR (multicentre; 2015-2023) and FISIOTON (single-centre; 2018-2024) - totalling 723 patients. Endothelial dysfunction was defined as any epicardial vasoconstriction to ACH or endothelium-dependent coronary flow reserve ≤1.5. MINOCA was diagnosed in 68 (9.4%) patients. Endothelial dysfunction was found in 57.4%, epicardial spasm in 7.05% and microvascular spasm in 1.94%, without differences between MINOCA and ANOCA. In multivariable regression, MINOCA was independently associated with resting chest pain (OR 3.63, 95% CI: 1.84-7.66), previous MI (OR 2.91, 95% CI: 1.29-6.30) and active smoking (OR 2.15, 95% CI: 1.04-4.30). Over a median follow-up of 3.0 years, major adverse cardiovascular events (MACE) occurred in 7.5% of patients. MINOCA (HR 2.81, 95% CI: 1.40-5.67, p = 0.004), endothelial dysfunction (HR 2.59, 95% CI: 1.29-5.21, p = 0.008) and male sex (HR 2.01, 95% CI: 1.13-3.58, p = 0.017) were independently associated with MACE. Patients with MINOCA and endothelial dysfunction had the highest event rate (19.4%). In patients with non-obstructive coronary arteries undergoing ACH testing, endothelial dysfunction and a MINOCA presentation were independently associated with adverse events, whereas classical spasm endotypes were not.
-
3. Clinical and procedural outcomes of IVUS-guided versus angiography-guided PCI in unprotected left main coronary disease: An updated meta-analysis of randomized controlled trials.
PMID:日期:2026-11-15The clinical benefit of intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) in patients with unprotected left main coronary artery disease (ULMCAD) remains uncertain. We performed an updated meta-analysis of randomized controlled trials (RCTs) comparing IVUS-guided versus angiography-guided PCI in ULMCAD. We performed a meta-analysis of RCTs identified through PubMed, Cochrane CENTRAL, Scopus, and Web of Science from inception through May 2026. The primary outcome was major adverse cardiovascular events (MACE) at the longest follow-up period. Dichotomous outcomes were analyzed as risk ratios (RRs) and continuous outcomes as mean differences (MDs), both with 95% confidence intervals (CIs). Four RCTs comprising 1446 patients were included. MACE showed no statistically significant difference between groups (RR 0.57, 95% CI 0.30-1.09; P = 0.09). However, following exclusion of OPTIMAL Trial in leave-one-out sensitivity analyses, IVUS-guided PCI was associated with a statistically significant reduction in the incidence of MACE. No significant differences were observed between IVUS-guided and angiography-guided PCI regarding cardiac mortality (RR 0.68, 95% CI 0.27-1.73; P = 0.41), myocardial infarction (RR 0.93, 95% CI 0.68-1.28; P = 0.66), target lesion revascularization (RR 0.67, 95% CI 0.36-1.22; P = 0.18), target vessel revascularization (RR 0.63, 95% CI 0.30-1.33; P = 0.22), or stent thrombosis (RR 0.78, 95% CI 0.22-2.70; P = 0.69). In this meta-analysis of randomized trials, the primary random-effects analyses showed no statistically significant benefit of IVUS-guided PCI over angiography-guided PCI for MACE or any of the evaluated secondary clinical outcomes in patients with ULMCAD. Findings from leave-one-out sensitivity analyses were exploratory and did not alter the neutral overall conclusion. Further adequately powered contemporary randomized trials are needed to determine whether IVUS guidance benefits selected patient or lesion subgroups.
-
4. Tracking arterial stiffness from childhood to adolescence: the role of adiposity and cardiometabolic factors.
PMID:日期:2026-11-15Carotid-femoral pulse wave velocity (PWV) is the gold standard measure of central arterial stiffness and a predictor of cardiovascular events in adults, with growing relevance in pediatric populations. Although PWV increases naturally with age, cardiometabolic risk factors may accelerate this process. This study compared carotid-femoral PWV between non-overweight and overweight/obese adolescents, evaluated its progression from prepubertal age to early adolescence, and identified independent determinants of arterial stiffness. This longitudinal study included 118 participants from the Generation XXI cohort (Porto, Portugal) assessed at ages 8-9 and 13-14 years. Carotid-femoral PWV was measured at both time points using a validated portable device. Anthropometric data, office blood pressure, and fasting blood samples for lipid profile, glucose, and insulin were collected. Body mass index (BMI) classification followed World Health Organization references. PWV increased significantly from childhood to adolescence (5.01 ± 0.47 to 6.30 ± 1.05 m/s; p < 0.001). At 13-14 years, overweight/obese adolescents had significantly higher PWV than non-overweight peers. PWV at 13-14 years correlated positively with BMI, BMI z-score, systolic and diastolic blood pressure, and fasting glucose. In adjusted models, PWV at 8-9 years (β = 0.39; p = 0.039) and BMI z-score at 13-14 years (β = 0.33; p < 0.001) remained independent predictors of PWV at 13-14 years. Arterial stiffness in early adolescence reflects both vascular tracking from childhood and concurrent adiposity. These findings support early vascular screening and weight management interventions during key developmental periods to optimize long-term cardiovascular health.
-
5. Valvular heart failure is a distinct heart transplant phenotype with comparable adjusted survival to other heart failure etiologies.
PMID:日期:2026-11-15Valvular heart failure (VHF) accounts for 1-5% of heart transplant listings. Comparative outcomes relative to other heart failure etiologies remain poorly characterized. This study defines the VHF phenotype and compares waitlist and transplant outcomes to other heart failure recipients. This retrospective cohort study uses the UNOS thoracic transplant database to analyze adult, first-time, heart-only listings with a diagnosis of heart disease. Patients were grouped by diagnosis as VHF or non-VHF. The primary outcome was waitlist events; post-transplant survival and outcomes were secondary analyses. Subgroup analysis was performed in the post-2018 allocation era. VHF recipients were older (55.3 vs 54.0 years, P = 0.004), more frequently female (36.1% vs 25.0%, P < 0.001), and had higher rates of prior cardiac surgery (P < 0.001) with greater pulmonary vascular burden. At time of listing, VHF recipients had higher ECMO rates (4.9% vs 2.5%, P < 0.001) and lower VAD use (17.3% vs 31.7%, P < 0.001). VHF diagnosis was not independently associated with transplantation rates (SHR 0.979, P = 0.749) but was associated with a 23% higher rate of waitlist death/too sick to transplant (SHR 1.233, P = 0.005). Post-transplant survival was not significantly different between groups (P = 0.812). Post guideline changes, the waitlist mortality difference was attenuated. VHF represents a distinct but transplantable phenotype of heart failure. Although VHF patients faced higher waitlist mortality risk, allocation framework revisions attenuated this difference, and post-transplant survival is comparable to non-VHF recipients. Independent predictors of mortality are patient-level risk factors, supporting early referral and optimization as the primary strategy for outcome improvement in this phenotype.
-
7. Tenascin-C differentiates obstructive from non-obstructive coronary artery disease in non-ST-elevation acute coronary syndrome.
7. Tenascin-C在非ST段抬高型急性冠状动脉综合征中区分阻塞性和非阻塞性冠状动脉疾病PMID:日期:2026-11-15Differentiating obstructive from non-obstructive coronary artery disease (CAD) at the time of acute coronary syndrome (ACS) diagnosis remains challenging, and there is a need for biomarkers that can provide clearer discrimination. This study aims to assess Tenascin-C's diagnostic utility in predicting significant coronary artery stenosis in individuals with ACS. In this prospective single-center observational study, 204 patients with NSTEMI or UAP who underwent invasive coronary angiography were included. Serum Tenascin-C levels were measured within 48 h using ELISA, and patients were classified as having critical (≥70%) or non-critical CAD based on blinded angiographic assessment. The relationship between Tenascin-C, critical stenosis, and GRACE and SYNTAX scores was evaluated using logistic regression, correlation analyses, and ROC curves. Tenascin-C levels demonstrated robust discriminative performance (AUC 0.85) and were considerably greater in patients with critical CAD among the 204 included patients. Tenascin-C was the sole independent predictor of critical stenosis in multivariate analysis. Tenascin-C showed a modest correlation with the GRACE score and a substantial correlation with the SYNTAX score. Tenascin-C maintained a good diagnostic accuracy (AUC 0.87) in individuals with borderline hs-TnT levels (12-52 ng/L). Tenascin-C demonstrated greater discriminative ability than hs-TnT for identifying critical coronary stenosis in patients with NSTEMI or UAP, particularly in the borderline troponin range. These findings suggest that Tenascin-C may provide complementary information to current biomarkers and support more precise clinical decision-making.
-
8. PARADIGM-HF eligibility in historical German HFrEF populations: clinical characteristics and 1-year outcomes.
PMID:日期:2026-11-15In the PARADIGM-HF trial, sacubitril/valsartan improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Because patients enrolled in randomized trials often differ from those in routine care, we assessed the proportion and characteristics of patients fulfilling PARADIGM-HF eligibility criteria in historical German HFrEF datasets and used the PARADIGM-HF enalapril arm as descriptive clinical context. We analyzed 7605 HFrEF patients enrolled between 1994 and 2013 in three German datasets (EVITA-HF, HeLuMa, INH). Full eligibility, including natriuretic peptide (NP) criteria, was assessable in 4442 patients and confirmed in 1828 (41.2%). Mean age was 63.8 ± 13.3 years, 23.1% were female, and ischemic heart disease was the predominant etiology (51.7%). Compared with non-PARADIGM patients, PARADIGM-like patients were older, had lower LVEF, higher NP concentrations, and more comorbidities. In an exploratory pooled Cox analysis, the unadjusted HR of the PARADIGM-like patients for one-year all-cause mortality was 1.17 (95% CI 0.97-1.40) and was attenuated to 1.08 (95% CI 0.90-1.30) after adjustment for age, sex, NYHA functional class III/IV, LVEF, and renal function. Descriptive contextualization against the PARADIGM-HF enalapril arm showed overlap in clinical characteristics but also differences in disease severity, biomarker concentrations, and ascertainment conditions. In these historical German HFrEF datasets, full PARADIGM-HF eligibility including NP criteria was confirmed in 41.2% of patients with completely assessable eligibility information, indicating that PARADIGM-HF included a high rate of patients seen in routine care. PARADIGM-like compared to non-PARADIGM-like patients exhibited a more advanced clinical profile.
-
9. Machine learning prediction of 30-day mortality in coronary artery disease: a retrospective multicenter study using electronic health records.
PMID:日期:2026-11-15Coronary artery disease (CAD) is the leading cause of death globally and a major contributor to hospital readmission. This study aimed to predict 30-day mortality in patients hospitalized with acute and chronic CAD using a structured machine learning approach with data from multiple centers. We conducted a retrospective cohort study using patient data from the Taipei Medical University Clinical Research Database (TMUCRD). Multiple machine learning algorithms were employed to develop predictive models for 30-day mortality. Model performance was evaluated using a stratified fivefold cross-validation approach. Key performance metrics included the area under the curve (AUC), accuracy, sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and F1 score. A total of 23,267 patients (mean age 64.9 years) were included, with 1215 deaths overall (5.2%): 570 (3.7%) in the internal cohort (n = 15,510) and 645 (8.3%) in the external validation cohort (n = 7757, Shuang Ho Hospital). XGBoost achieved the best performance for the overall and acute CAD cohorts (AUROC 0.845 and 0.820, respectively), while logistic regression performed best for chronic CAD (AUROC 0.766). Key predictive features included the Charlson Comorbidity Index, hemoglobin level, emergency room admission status, age, and creatinine level. The use of a structured machine learning approach to predict 30-day mortality in patients with acute and chronic CAD demonstrated promising discriminative performance, providing valuable insights that could enhance personalized care and inform clinical decisions.
-
10. NT-proBNP as a marker of coronary artery disease burden in chronic coronary syndromes.
PMID:日期:2026-11-15Evidence regarding the role of N-terminal pro-brain natriuretic peptide (NTproBNP) in chronic coronary syndrome (CCS) remains limited. We aimed to investigate the association between plasma NTproBNP levels and the presence and extent of coronary artery disease (CAD) in a prospective real-world cohort. This prospective observational cross-sectional study included 676 consecutive patients (mean age 67 ± 7 years; 20% women) referred for elective coronary angiography for suspected CCS, as part of the BNP-CAD study (ClinicalTrials.govNCT07013344). Patients with conditions known to elevate NTproBNP were excluded. Obstructive CAD was defined as stenosis ≥70% (≥50% for the left main). Prognostically significant CAD was defined as involvement of the left main or proximal LAD artery. Obstructive CAD was identified in 432 patients (64%). NTproBNP levels were significantly higher in patients with obstructive CAD compared to those without (124 vs. 96 pg/mL, p < 0.001) and increased with the number of vessels involved and degree of stenosis. After adjustment for clinical confounders and high-sensitivity troponin T, NT-proBNP remained independently associated with obstructive CAD (OR per 100 pg/mL increase: 1.18; 95% CI: 1.03-1.36; p = 0.021). Prognostically significant CAD was present in 197 patients (46% of those with obstructive CAD) and was associated with higher NT-proBNP levels (133 vs. 107 pg/mL; p = 0.006), although discriminatory performance remained modest (AUC: 0.60; 95% CI: 0.55-0.64). NT-proBNP was independently associated with obstructive CAD and correlated with coronary disease burden. However, its modest discriminatory performance precludes its use as a stand-alone diagnostic test for high-risk coronary anatomy.